The promise of continuous metabolic monitoring has always been shadowed by a simple, painful reality: the needle. For the millions managing diabetes, or athletes tracking lactate, or anyone curious about their ketones, the gold standard remains a blood draw or a finger prick. Synex Medical, a Toronto-based startup, is betting that the future of this data is not a lancet, but a magnet.
Founded in 2017 by a teenager who was once detained at the U.S. border for transporting an 80-pound magnet for a homemade MRI, Synex is developing compact devices that use magnetic resonance spectroscopy to measure blood metabolites in real time [TechCrunch, September 2024]. The company’s recent C$21.8 million Series A round, bringing its total disclosed funding to roughly $27 million, signals investor confidence in a deeply technical, and deeply humane, ambition: to make predictive, molecular-level health data accessible without a single drop of blood [Osler, September 2024].
The physics-first wedge
Synex’s differentiation is not a novel sensor chemistry or a more comfortable adhesive patch. It is a fundamental shift in the underlying physics of measurement. The company’s technology applies the same principles used in hospital MRI machines,magnetic fields and radio waves,but miniaturizes them into a form factor intended for the home. The goal is to non-invasively detect the unique magnetic resonance signatures of molecules like glucose, lactate, and ketones as they circulate in the blood vessels of a fingertip [Synex Medical].
This approach, if clinically validated, would sidestep the major limitations of current technologies. Continuous glucose monitors (CGMs), while revolutionary, still require a subcutaneous sensor that must be replaced every 10 to 14 days. Traditional lactate testing for athletes involves a pinprick blood sample. Synex’s vision is a single, needle-free device that can track a panel of metabolites, moving from single-parameter monitoring to a more holistic metabolic dashboard.
A founder’s story and a seasoned team
The company’s origin is unusual, even for biotech. Founder and CEO Ben Nashman started Synex Medical while still in high school, driven by a fascination with magnetic resonance and its potential for medicine [Synex Medical, retrieved 2024]. The now-famous customs incident, where he was stopped with a large magnet, underscores a founder’s preternatural focus on the core hardware challenge from day one.
To scale that vision into a regulated medical device, Synex has built a team that blends deep technical expertise with commercial experience. The leadership includes President John Capodilupo, a co-founder of the wearable giant WHOOP, whose background in consumer health technology and performance monitoring aligns directly with Synex’s aspirational use cases [LinkedIn, retrieved 2026]. The technical roster features specialists in nuclear magnetic resonance science, radio-frequency engineering, and industrial design, as evidenced by active hiring for roles like Principal MRS Scientist and Staff RF Engineer [Synex Medical, retrieved 2024].
| Role | Name | Notable Background |
|---|---|---|
| Chief Executive Officer | Ben Nashman | Founded company in high school; TKS alum |
| President | John Capodilupo | Co-founder of WHOOP |
| Director of Product | Houston Keil-Vine | Holds multiple hardware patents |
| Senior NMR Scientist II | Yonatan Hovav, PhD | Magnetic resonance specialization |
| Senior Industrial Designer | Borys Chylinski | Product design |
| Senior Electrical Engineer | Christina Riczu | Hardware engineering |
The path to the clinic and the consumer
Synex’s public messaging points toward a dual-track strategy. One path is a consumer-oriented wearable, hinted at in materials describing a “One Ring” concept paired with a smartphone app for continuous health insights [Perplexity Sonar Pro Brief]. The other, arguably more consequential path, leads into clinical and professional settings for predictive medicine. The multi-metabolite capability could provide value in managing metabolic syndrome, monitoring critical care patients, or optimizing athletic performance.
However, the leap from compelling physics to an FDA-cleared device is a formidable one. The risks for Synex are not about competition from named rivals, but about the inherent difficulty of the technical and regulatory journey.
- Clinical validation. The core risk is proving that magnetic resonance readings from a fingertip correlate accurately and reliably with gold-standard blood serum measurements across a diverse patient population. This requires rigorous, peer-reviewed studies.
- Regulatory complexity. A device that provides diagnostic information, especially for glucose management in diabetes, will face intense scrutiny from the FDA. The path to a De Novo classification or 510(k) clearance is long, expensive, and uncertain.
- Form factor and usability. Miniaturizing MRI-grade hardware into a device that is truly portable, affordable, and easy for consumers to use correctly represents a significant engineering challenge.
The company’s recent $21.8 million Series A provides the capital to confront these challenges head-on. The absence of a disclosed lead investor is notable, but the participation of firms like Accomplice and Radical Ventures, alongside angels like Naval Ravikant, suggests a belief in the foundational technology [CB Insights, retrieved 2024].
What standard care looks like today
For the patient populations Synex ultimately aims to serve, the current standard of care involves frequent compromise. Individuals with diabetes who use CGMs gain continuous data but must tolerate an implanted sensor and regular calibrations with finger-stick blood glucose meters. Athletes and coaches seeking real-time lactate thresholds to guide training intensity typically rely on intermittent, invasive blood sampling during stress tests. The pursuit of metabolic health through ketosis or glucose stability is often conducted blindly, with insights lagging hours behind a blood draw.
Synex Medical’s bet is that within the next few years, this landscape can change. The next twelve months will be critical for moving from prototype to pivotal trial, translating magnetic resonance signals into regulatory submissions. If they succeed, the impact would be measured not in megabytes of data, but in the relief of patients who never have to prick their finger again.
Sources
- [TechCrunch, September 2024] Synex founder, once detained at the border with an 80-pound magnet, is building portable MRIs to test glucose | https://techcrunch.com/2024/09/22/synex-founder-once-detained-at-the-border-with-a-80-pound-magnet-is-building-portable-mris-to-test-glucose/
- [Osler, September 2024] Osler advises Synex Medical on its C$21.8 million oversubscribed Series A financing | https://www.osler.com/en/about-us/representative-work/synex-medical-2/
- [Synex Medical] Company website and careers page | https://synexmedical.com/
- [Perplexity Sonar Pro Brief] Web-grounded research summary on Synex Medical | Derived from multiple sources including PitchBook and CB Insights
- [LinkedIn, retrieved 2026] Profile for John Capodilupo | https://www.linkedin.com/in/ben-nashman-5b509a12b/
- [CB Insights, retrieved 2024] Synex Medical Company Information - Funding, Investors, and More | https://www.cbinsights.com/company/synex-medical/financials